Lanean...
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
PURPOSE: Poly(ADP-ribose) polymerase plays an important role in DNA repair and PARP inhibitors can enhance the activity of DNA damaging agents in vitro and in vivo. AG014699 is a potent PARP inhibitor in Phase II clinical development. However the range of therapeutics with which AG014699 could inter...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2009
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2756456/ https://ncbi.nlm.nih.gov/pubmed/19789326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0398 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|